drugset
drugset / Trial / NCT05582707

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

NCT05582707 ↗

Phase 2 Terminated 1 enrolled University of Maryland, Baltimore Nico Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH trial. This study will take approximately two years to complete.

Timeline

Start
2023-05-08
Primary completion
2024-09-19
Completion
2025-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 15 mg Oral

Indications

intracerebral hemorrhage